Lakefront Biotherapeutics (LKFT) Beginning Cash Balance (2019 - 2021)

Lakefront Biotherapeutics (LKFT) has reported Beginning Cash Balance for 5 consecutive years, with $102.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Beginning Cash Balance rose 52.24% year-over-year to $102.9 million; the TTM figure through Mar 2026 stood at $170.4 million (down 31.49% YoY), while the FY2016 annual figure was $376.7 million, up 83.11% from the prior year.
• Beginning Cash Balance grew to $102.9 million in Q1 2026 per LKFT's latest filing, from $67.6 million in the prior quarter.
• Across five years, Beginning Cash Balance topped out at $181.2 million in Q1 2024 and bottomed at $67.6 million in Q1 2025.
• Historically, Beginning Cash Balance has averaged $117.2 million across 3 years, with a median of $102.9 million in 2026.
• Annual changes were most pronounced in 2025 — Beginning Cash Balance tumbled 62.71% — and 2026, when it soared 52.24%.
• Lakefront Biotherapeutics' Beginning Cash Balance stood at $181.2 million in 2024, then sank by 62.71% to $67.6 million in 2025, then soared by 52.24% to $102.9 million in 2026.
• Business Quant data shows LKFT's Beginning Cash Balance at $102.9 million in Q1 2026, $67.6 million in Q1 2025, and $181.2 million in Q1 2024.